Quindós Guillermo, Villar-Vidal María, Eraso Elena
Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco-Euskal Herriko Unibertsitatea, Bilbao, Vizcaya, España.
Rev Iberoam Micol. 2009 Mar 31;26(1):49-55. doi: 10.1016/S1130-1406(09)70008-7. Epub 2009 May 7.
Most recalcitrant infections are associated to colonization and microbial biofilm development. These biofilms are difficult to eliminate by the immune response mechanisms and the current antimicrobial therapy.
To describe the antifungal of micafungin against fungal biofilms based in the scientific and medical literature of recent years.
We have done a bibliographic retrieval using the scientific terms "micafungin", "activity", "biofilm", "Candida", "Aspergillus", "fungi", "mycos"*, susceptibility, in PubMed/Medline from the National Library of Medicine from 2006 to 2009.
Most current antifungal agents (amphotericin B and fluconazole) and the new azole antifungals have no activity against fungal biofilms. However, micafungin and the rest of echinocandins are very active against Candida albicans, Candida dubliniensis, Candida glabrata, and Candida krusei biofilms but their activities are variable and less strong against Candida tropicalis and Candida parapsilosis biofilms. Moreover, they have not activities against the biofilms of Cryptococcus y Trichosporon.
The activity of micafungin against Candida biofilms gives more strength to its therapeutic indication for candidaemia and invasive candidiasis associated to catheter, prosthesis and other biomedical devices.
大多数顽固性感染与定植及微生物生物膜形成有关。这些生物膜难以通过免疫反应机制和当前的抗菌疗法清除。
根据近年来的科学和医学文献描述米卡芬净对真菌生物膜的抗真菌作用。
我们使用“米卡芬净”“活性”“生物膜”“念珠菌属”“曲霉属”“真菌”“霉菌”*“敏感性”等科学术语在国立医学图书馆的PubMed/Medline中进行了2006年至2009年的文献检索。
大多数现有的抗真菌药物（两性霉素B和氟康唑）以及新型唑类抗真菌药物对真菌生物膜无活性。然而，米卡芬净和其他棘白菌素类药物对白色念珠菌、都柏林念珠菌、光滑念珠菌和克柔念珠菌生物膜具有很强的活性，但对热带念珠菌和近平滑念珠菌生物膜的活性可变且较弱。此外，它们对新型隐球菌和毛孢子菌的生物膜无活性。
米卡芬净对念珠菌生物膜的活性为其用于治疗念珠菌血症以及与导管、假体和其他生物医学装置相关的侵袭性念珠菌病的治疗指征提供了更强的依据。
